Literature DB >> 30222703

Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.

Marci D Cottingham1, Julianne M Kalbaugh2, Teresa Swezey3, Jill A Fisher2.   

Abstract

As with all early-stage testing of investigational drugs, clinical trials targeting HIV/AIDS can pose unknown risks to research subjects. Unlike sick participants seeking a therapeutic benefit, the motivations and barriers for healthy volunteers are more complex and understudied. Drawing on interviews and clinical trial data from 178 healthy volunteers, we examine how they perceive HIV/AIDS studies in the early stages of testing. A subset of healthy volunteers see phase I HIV/AIDS studies as particularly risky for reasons ranging from fear of catching the disease or having long-lasting and uncomfortable side effects to inexplicable fears that they cannot even articulate. Some participants have had past negative experiences in such trials that inform these views, but others cite information from staff and other participants as influential. Healthy volunteers' general fears concerning AIDS also shape their views of participating in phase I HIV/AIDS clinical trials.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30222703      PMCID: PMC6373478          DOI: 10.1097/QAI.0000000000001818

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  37 in total

1.  French drug trial had three major failings, says initial report.

Authors:  Nigel Hawkes
Journal:  BMJ       Date:  2016-02-08

Review 2.  Barriers to participation in HIV drug trials: a systematic review.

Authors:  Edward Mills; Kumanan Wilson; Beth Rachlis; Lauren Griffith; Ping Wu; Gordon Guyatt; Curtis Cooper
Journal:  Lancet Infect Dis       Date:  2006-01       Impact factor: 25.071

3.  Concealment and fabrication by experienced research subjects.

Authors:  Eric G Devine; Megan E Waters; Megan Putnam; Caitlin Surprise; Katie O'Malley; Courtney Richambault; Rachel L Fishman; Clifford M Knapp; Elissa H Patterson; Ofra Sarid-Segal; Chris Streeter; Laurie Colanari; Domenic A Ciraulo
Journal:  Clin Trials       Date:  2013-07-18       Impact factor: 2.486

4.  Concealment and fabrication: the hidden price of payment for research participation?

Authors:  Neal W Dickert
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

5.  "Ready-to-Recruit" or "Ready-to-Consent" Populations?: Informed Consent and the Limits of Subject Autonomy.

Authors:  Jill A Fisher
Journal:  Qual Inq       Date:  2007-09

6.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

7.  Subversive subjects: rule-breaking and deception in clinical trials.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

8.  Engaging members of African American and Latino communities in preventive HIV vaccine trials.

Authors:  Magdalena E Sobieszczyk; Guozhen Xu; Krista Goodman; Debbie Lucy; Beryl A Koblin
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

9.  Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies.

Authors:  Ezekiel J Emanuel; Gabriella Bedarida; Kristy Macci; Nicole B Gabler; Annette Rid; David Wendler
Journal:  BMJ       Date:  2015-06-26

10.  Participation in HIV cure-related research: a scoping review of the proxy literature and implications for future research.

Authors:  Karine Dubé; Catalina Ramirez; Jessica Handibode; Jeffrey Taylor; Asheley Skinner; Sandra Greene; Joseph D Tucker
Journal:  J Virus Erad       Date:  2015-10
View more
  1 in total

1.  Picking and Choosing Among Phase I Trials : A Qualitative Examination of How Healthy Volunteers Understand Study Risks.

Authors:  Jill A Fisher; Torin Monahan; Rebecca L Walker
Journal:  J Bioeth Inq       Date:  2019-11-12       Impact factor: 1.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.